A Novel Immune-Related lncRNA-Based Model for Survival Prediction in Clear Cell Renal Cell Carcinoma

Figure 5

Principal component analysis of three sets and Kaplan-Meier survival analysis of the five-lncRNA signature in different subgroups of clinical parameters. (a–c) Principal component analysis of the training set, the testing set, and the whole set based on the 5-lncRNA expression. (d–f) Principal component analysis of the training set, the testing set, and the whole set based on the whole immune-related lncRNA expression. The red dots represent the high-risk patients, while the blue dots represent the low-risk patients. (g–l) Survival analysis of the five-lncRNA signature in stages I and II, stages III and IV, grades 1 and 2, grades 3 and 4, metastasis, without metastasis, pharmaceutical, without pharmaceutical, male, female, elder, and younger.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)